SAFETY AND EFFICACY OF COMBINED RITODRINE AND MAGNESIUM-SULFATE FOR PRETERM LABOR - A METHOD FOR REDUCTION OF COMPLICATIONS

被引:11
作者
COLEMAN, FH [1 ]
机构
[1] DARNALL ARMY COMMUNITY HOSP,DEPT OBSTET & GYNECOL,FT HOOD,TX
关键词
D O I
10.1055/s-2007-999525
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Ritodrine hydrochloride and magnesium sulfate used in combination for preterm labor tocolysis have been cited for yielding excessively high complication rates. A retrospective chart review was performed to assess the frequency of these complications and to determine whether tocolysis can be continued despite complications. Of 95 patients managed with dual tocolytics, 61 had side effects sufficiently serious to warrant cessation of tocolytic therapy for an overall complication rate of 64%. After evaluation for objective evidence of pathologic conditions, 41 (67%) patients were restarted on dual tocolytics without further complication. It was deemed inappropriate to restart tocolysis in 20 patients, resulting in a 21% rate of complications. This allowed a significant increase in the number of patients delivering after 36 weeks (19.5% versus 50%, p < 0.02) and a decrease in neonatal intensive care unit days per infant (3 versus 15.5 days, p < 0.02). This suggests that aggressive continued tocolysis with multiple agents can be safe and efficacious with appropriate evaluation. © 1990 by Thieme Medical Publishers, Inc. All rights reserved.
引用
收藏
页码:366 / 369
页数:4
相关论文
共 10 条
  • [1] Eggleston M.K., Management of preterm labor and delivery, Clin Obstet Gynecol, 29, pp. 230-239, (1986)
  • [2] Beall M.H., Edgar B.W., Paul R.H., Et al., A comparison of ritodrine, terbutaline, and magnesium sulfate for the suppression of preterm labor, Am J Obstet Gynecol, 153, pp. 854-859, (1985)
  • [3] Benedetti T.J., Maternal complications of parenteral beta-sympathomimetic therapy for premature labor, Am J Obstet Gynecol, 145, pp. 1-6, (1983)
  • [4] Katz M., Robertson P.A., Creasy R.K., Cardiovascular complications associated with terbutaline treatment for preterm labor, Am J Obstet Gynecol, 136, pp. 605-608, (1981)
  • [5] Bardert T.F., Peter J.B., Merkatz I.R., Ritodrine hydrochloride: A betamimetic agent for use in preterm labor, Obstet Gynecol, 56, pp. 1-6, (1980)
  • [6] Wilkins L.A., Lynch L., Mehalek K.E., Et al., Efhcacy and side effects of magnesium sulfate and ritodrine as tocolytic agents, Am J Obstet Gynecol, 159, pp. 685-689, (1988)
  • [7] Leveno K.J., Guzick D.S., Hankins G.D.V., Et al., Single-centre randomized trial of ritodrine hydrochloride for preterm labor, Lancet, 1, pp. 1293-1295, (1986)
  • [8] Ingermarsson I., Arulkumaran S., Kottegoda S.R., Complications of beta-mimetic therapy in preterm labor, Aust NZ J Obstet Gynecol, 35, pp. 182-189, (1985)
  • [9] Caritis S.N., Lin L.S., Torg G., Et al., Pharmacodynamics of ritodrine in pregnant women during preterm labor, Am J Obstet Gynecol, 147, pp. 752-759, (1983)
  • [10] Hendricks S.K., Keroes J., Katz M., Electrocardiographic changes associated with ritodrine-induced maternal tachycardia and hypokalemia, Am J Obstet Gynecol, 154, pp. 921-923, (1986)